EGFR and non-small cell lung carcinoma: Additionally, BDTX-1535, an orally bioavailable, potent, selective, and irreversible allosteric EGFR inhibitor, has shown promising preliminary efficacy and durability in Phase II trials in patients with relapsed or refractory EGFR-mutant NSCLC [39,40].